Nebivolol ( DrugBank: Nebivolol )

---

4 diseases

ID	Disease name (Link within this page)	Number of trials
17	Multiple system atrophy	1
85	Idiopathic interstitial pneumonia	1
113	Muscular dystrophy	2
167	Marfan syndrome	2

17. Multiple system atrophy

---

Clinical trials : 119 /  Drugs : 138 - (DrugBank : 44) / Drug target genes : 59 - Drug target pathways : 111

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01044693 (ClinicalTrials.gov)	January 2010	6/1/2010	Nebivolol in the Supine Hypertension of Autonomic Failure	Effect of Nebivolol on Blood Pressure in a Model of Hypertension Sensitive to Potentiation of Nitric Oxide Bioactivity	Hypertension;Pure Autonomic Failure;Multiple System Atrophy	Drug: Placebo;Drug: Nebivolol 5 mg;Drug: metoprolol tartrate 50 mg;Drug: Sildenafil25 mg	Vanderbilt University	Forest Laboratories	Completed	18 Years	80 Years	All	20	N/A	United States

85. Idiopathic interstitial pneumonia

---

Clinical trials : 627 /  Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04888728 (ClinicalTrials.gov)	June 30, 2021	28/4/2021	To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers	An Open Label, 2-part, One-sequence, 3-period Study to Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Male Volunteers	Idiopathic Pulmonary Fibrosis	Drug: DWN12088;Drug: Nebivolol;Drug: Paroxetine	Daewoong Pharmaceutical Co. LTD.	NULL	Completed	20 Years	55 Years	Male	24	Phase 1	Korea, Republic of

113. Muscular dystrophy

---

Clinical trials : 646 /  Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01648634 (ClinicalTrials.gov)	February 13, 2012	20/7/2012	Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy	A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Examine the Effect of Nebivolol, a Beta-Blockade Drug, for the Prevention of Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy	Duchenne Muscular Dystrophy;Cardiomyopathy;Heart Failure	Drug: Nebivolol;Drug: Placebo	Assistance Publique - Hôpitaux de Paris	Association Française contre les Myopathies (AFM), Paris	Completed	10 Years	15 Years	Male	51	Phase 3	France
2	EUCTR2010-020047-12-FR (EUCTR)		01/04/2011	Effet d’un traitement préventif par Nebivolol chez les enfants atteints de dystrophie de Duchenne	Etude de l'effet d'un traitement préventif par Nebivolol sur l'apparition et la progression de la dysfonction cardiaque chez les enfants atteints de dystrophie de Duchenne - NEBIDYS	Enfants atteints de dystrophie de Duchenne MedDRA version: 13.1;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Temerit Product Name: Temerit INN or Proposed INN: Nébivolol	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	Not Recruiting			Female: no Male: yes	70	Phase 3	France

167. Marfan syndrome

---

Clinical trials : 21 /  Drugs : 40 - (DrugBank : 11) / Drug target genes : 10 - Drug target pathways : 50

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2008-001462-81-IT (EUCTR)	27/10/2008	17/03/2008	Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND	Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND	Marfan Syndrome MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome	Trade Name: LORTAAN*28CPR RIV DIV 50MG INN or Proposed INN: Losartan Trade Name: LOBIVON*28CPR 5MG INN or Proposed INN: Nebivolol	OSPEDALE POLICLINICO S. MATTEO	NULL	Not Recruiting			Female: yes Male: yes		Phase 3	Italy
2	NCT00683124 (ClinicalTrials.gov)	July 2008	21/5/2008	Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients	Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.	Marfan Syndrome	Drug: Losartan and nebivolol;Drug: Losartan;Drug: Nebivolol	IRCCS Policlinico S. Matteo	Merck Sharp & Dohme Corp.;Menarini Group	Recruiting	12 Months	55 Years	Both	291	Phase 3	Italy

Back to top